Biomica plans to use the $20 million in new funding from Shanghai Healthcare Capital to further develop its pipeline of microbiome-based therapeutics.

Biomica plans to use the $20 million in new funding from Shanghai Healthcare Capital to further develop its pipeline of microbiome-based therapeutics.